Linxin Zhang

Linxin Zhang

Auto-generated profile, based on publicly available information

Linxin Zhang

Complementary and Integrative Digital Health, Institute of Primary Care, University of Zurich and University Hospital Zurich, Zürich, Switzerland

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2023 in Cancer Medicine
Verified
Journal Article
Open access
YYYuqian Yan
Yuqian Yan
JLJesús López‐Alcalde
Jesús López‐Alcalde
LZLinxin Zhang
Linxin Zhang
Alexander Reinhard SiebenhünerAlexander Reinhard Siebenhüner
Alexander Reinhard Siebenhüner
CWClaudia M. Witt
Claudia M. Witt
JBJürgen Barth
Jürgen Barth
Purpose: To assess the effectiveness and safety of acupuncture for the prevention of chemotherapy‐induced nausea and vomiting (CINV), with a specific intention on exploring sources of between‐study variation in treatment effects.Methods: MEDLINE, EMBASE, Cochrane CENTRAL, CINAHL, Chinese Biomedical Literature Database, VIP Chinese Science and Technology Periodicals Database, China National Knowledge Infrastructure, and Wanfang were searched to identify randomized controlled trials (RCTs) that compared acupuncture to sham acupuncture or usual care (UC). The main outcome is complete control (no vomiting episodes and/or no more than mild nausea) of CINV. GRADE approach was used to rate the certainty of evidence.Results: Thirty‐eight RCTs with a total of 2503 patients were evaluated. Acupuncture in addition to UC may increase the complete control of acute vomiting (RR, 1.13; 95% CI, 1.02 to 1.25; 10 studies) and delayed vomiting (RR, 1.47; 95% CI, 1.07 to 2.00; 10 studies) when compared with UC only. No effects were found for all other review outcomes. The certainty of evidence was generally low or very low. None of the predefined moderators changed the overall findings, but in an exploratory moderator analysis we found that an adequate reporting of planned rescue antiemetics might decrease the effect size of complete control of acute vomiting (p = 0.035).Conclusion: Acupuncture in addition to usual care may increase the complete control of chemotherapy‐induced acute vomiting and delayed vomiting but the certainty of evidence was very low. Well‐designed RCTs with larger sample sizes, standardized treatment regimens, and core outcome measures are needed.

10 March 2023 in BMJ Open
Verified
Journal Article
Open access
PDF file
CHChristine Huber
Christine Huber
LZLinxin Zhang
Linxin Zhang
MSMarc Schlaeppi
Marc Schlaeppi
TMTwyla Müller
Twyla Müller
SRStephanie Roll
Stephanie Roll
CWClaudia M Witt
Claudia M Witt
Introduction Dysgeusia is a common side effect of chemotherapy in patients with cancer, but to date, there is no effective treatment. Many patients with cancer request complementary medicine treatment in addition to their cancer treatments, and acupuncture is highly accepted for patients with cancer; however, evidence regarding the effectiveness of acupuncture for dysgeusia is scarce. The study investigates the effectiveness of an additional dysgeusia-specific acupuncture plus self-acupressure intervention compared with supportive acupuncture plus self-acupressure intervention alone for chemotherapy-induced dysgeusia in patients with cancer. Methods and analysis This is a multicentre, randomised, controlled and two-armed parallel-group, single-blind trial involving 130 patients. Both groups will receive eight sessions of acupuncture treatment over a period of 8 weeks and will be trained to perform self-acupressure (eLearning combined with therapist instruction) at predefined acupressure points once a day during the whole treatment period. Patients in the control group will receive supportive routine care acupuncture and self-acupressure treatment only; in addition to this treatment, the intervention group will receive the dysgeusia-specific acupuncture and acupressure within the same treatment session. The primary outcome is the perceived dysgeusia over 8 weeks, measured weekly after the acupuncture treatment. Secondary outcomes include the indices from the objective taste and smell test, weight loss, perceived dysgeusia, fatigue, distress, nausea and vomiting, odynophagia, xerostomia and polyneuropathy, as well as quality of life at the different time points. Ethics and dissemination The study has been approved by the Cantonal Ethics Committee (CEC) (Kanton Zürich Kantonale Ethikkommission) (approval no. KEK-ZH-Nr. 2020–01900). The results will be submitted to a peer-reviewed journal for publication. Trial registration numbers DRKS00023348, SNCTP000004128.

13 May 2026 in Supportive Care in Cancer
Verified
Journal Article
Open access
PDF file
CHChristine Huber
Christine Huber
JBJürgen Barth
Jürgen Barth
LBLea Bührer
Lea Bührer
CDChristoph Driessen
Christoph Driessen
UHUlrike Held
Ulrike Held
CWClaudia M. Witt
Claudia M. Witt
Purpose The study investigated the effectiveness of dysgeusia-specific acupuncture combined with self-acupressure compared to supportive acupuncture and self-acupressure for chemotherapy-induced dysgeusia in cancer patients with cancer-related fatigue (CRF) and dysgeusia. Methods This multicenter, randomized, controlled, two-armed parallel-group, single-blind trial included cancer patients with CRF and dysgeusia during chemotherapy. All participants received CRF treatment consisting of eight acupuncture sessions over 8 weeks and had access to an eLearning course for self-acupressure. Patients in the intervention group received additional dysgeusia-specific acupuncture treatment and an eLearning with instructions to acupressure points, whereas the control group received an intervention focused solely on addressing CRF. The main outcome was perceived dysgeusia over 8 weeks, measured weekly after each acupuncture session on a numeric rating scale from 1 to 10. Other outcomes included taste and smell tests, and assessments of perceived dysgeusia, fatigue, distress, and quality of life. Due to a small sample size, results can be only judged exploratory. The study was approved by the Cantonal Ethics Committee (CEC) (Kanton Zürich Kantonale Ethikkommission) (approval no. KEK-ZH-Nr. 2020—01900). Results Since we included only twenty-one patients (11 intervention, 10 control, 90% female) instead of the target sample size of 130, no confirmatory effectiveness analyses were conducted. All participants showed a substantial decrease in dysgeusia over time, regardless of treatment type (estimated mean reduction per session − 0.30; 95% CI − 0.43 to − 0.18), reflecting a 0.30-point reduction per session. Quality of life and cancer-related fatigue improved over time. The exploratory analyses did not show substantial differences between groups in any outcomes. No serious adverse events occurred. Conclusions Exploratory findings showed no substantial differences between the study groups in perceived dysgeusia, but both study groups improved over time. Trial registration number DRKS00023348 at 03.11.2020, SNCTP000004128.